scholarly journals The Impact of Aspirin Resistance on the Long-term Cardiovascular Mortality in Patients with Non-ST Segment Elevation Acute Coronary Syndromes

2009 ◽  
Vol 32 (3) ◽  
pp. 142-147 ◽  
Author(s):  
Stefanos G. Foussas ◽  
Michael N. Zairis ◽  
Vasilios G. Tsirimpis ◽  
Stamatis S. Makrygiannis ◽  
Nikolaos G. Patsourakos ◽  
...  
Keyword(s):  
Cardiovascular Mortality ◽  
Acute Coronary Syndromes ◽  
Aspirin Resistance ◽  
St Segment Elevation ◽  
St Segment ◽  
Coronary Syndromes ◽  
The Impact

Fibrinolytic, antiplatelet, and anticoagulant drugs in acute coronary syndromes

2021 ◽  
pp. 494-512
Author(s):  
Sigrun Halvorsen ◽  
Giuseppe Gargiulo ◽  
Marco Valgimigli ◽  
Kurt Huber
Keyword(s):  
Acute Coronary Syndromes ◽  
Plaque Rupture ◽  
Thrombus Formation ◽  
Coronary Intervention ◽  
Fibrinolytic Therapy ◽  
St Segment Elevation ◽  
St Segment ◽  
Coronary Syndromes ◽  
Activation Pathways

Antithrombotic therapy is a major cornerstone in the treatment of acute coronary syndromes (ACS), as thrombus formation upon a plaque rupture or an erosion plays a pivotal role in non-ST-segment elevation as well as ST-segment elevation acute coronary syndromes. Both acute and long-term oral antiplatelet therapies, targeting specific platelet activation pathways, have demonstrated significant short- and long-term benefits. The use of anticoagulants is currently largely confined to the acute setting, except in patients with a clear indication for long-term treatment, including atrial fibrillation or the presence of intraventricular thrombi. Despite the benefit of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction, fibrinolytic therapy continues to play an important role throughout the world. In this chapter, the fibrinolytic, antiplatelet, and anticoagulant agents used in the management of acute coronary syndrome patients are discussed.

Sign in / Sign up

Export Citation Format

Share Document